Maxwell Russell, Luksik Andrew S, Garzon-Muvdi Tomas, Lim Michael
Department of Neurosurgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Neurosurgery - Phipps 123, Baltimore, MD, 21287, USA.
Curr Neurol Neurosci Rep. 2017 Jun;17(6):50. doi: 10.1007/s11910-017-0754-x.
Malignant gliomas, including glioblastoma and anaplastic astrocytoma, are the most frequent primary brain tumors and present with many treatment challenges. In this review, we discuss the potential of cellular- and viral-based immunotherapies in the treatment of malignant glioma, specifically focusing on dendritic cell vaccines, adoptive cell therapy, and oncolytic viruses.
Diverse cellular- and viral-based strategies have been engineered and optimized to generate either a specific or broad antitumor immune response in malignant glioma. Due to their successes in the preclinical arena, many of these therapies have undergone phase I and II clinical testing. These early clinical trials have demonstrated the feasibility, safety, and efficacy of these immunotherapies. Dendritic cell vaccines, adoptive cell transfer, and oncolytic viruses may have a potential role in the treatment of malignant glioma. However, these modalities must be investigated in well-designed phase III trials to prove their efficacy.
恶性胶质瘤，包括胶质母细胞瘤和间变性星形细胞瘤，是最常见的原发性脑肿瘤，存在诸多治疗挑战。在本综述中，我们讨论基于细胞和病毒的免疫疗法在恶性胶质瘤治疗中的潜力，特别关注树突状细胞疫苗、过继性细胞疗法和溶瘤病毒。
已设计并优化了多种基于细胞和病毒的策略，以在恶性胶质瘤中产生特异性或广泛的抗肿瘤免疫反应。由于它们在临床前领域取得的成功，其中许多疗法已进入I期和II期临床试验。这些早期临床试验已证明了这些免疫疗法的可行性、安全性和有效性。树突状细胞疫苗、过继性细胞转移和溶瘤病毒可能在恶性胶质瘤治疗中发挥潜在作用。然而，这些方法必须在精心设计的III期试验中进行研究，以证明其疗效。
